Innate Pharma Names Jonathan Dickinson CEO, Executive Board Chairman

Dow Jones
14 Oct 2024
 

By Colin Kellaher

 

Innate Pharma has hired Jonathan Dickinson as the clinical-stage biotechnology company's next chief executive.

Innate said Dickinson, who most recently served as executive vice president and general manager for Europe at Incyte, joins the France-based company on Nov. 1 and will also serve as chairman of the executive board.

Herve Brailly, Innate's co-founder, has been serving as interim CEO and executive board chairman since the departure of Mondher Mahjoubi in January.

Innate said Brailly will remain for the next few months in an advisory role to assist with the transition, adding that it will propose that he join the board at the next opportunity.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

October 14, 2024 07:40 ET (11:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10